Alpha-synuclein and chaperones in dementia with Lewy bodies

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 12, 2005, Pages 1058-1066

  Cantuti Castelvetri, Ippolita ^a   Klucken, Jochen ^b   Ingelsson, Martin ^a   Ramasamy, Karunya ^a   McLean, Pamela J ^a   Frosch, Matthew P ^a   Hyman, Bradley T ^a   Standaert, David G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CNY114 2004 ^*

Author keywords

Alpha synuclein; Dementia with Lewy bodies; Molecular chaperone; Real time PCR; Temporal cortex

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; HDJ1 PROTEIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MESSENGER RNA; TRITON X 100; UNCLASSIFIED DRUG; DETERGENT; DNAJB1 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 40; OCTOXINOL;

ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CYTOTOXICITY; DEMENTIA; DEMENTIA WITH LEWY BODY; EXPERIMENTAL MODEL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LEWY BODY; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONTENT; REAL TIME POLYMERASE CHAIN REACTION; SOLUBILITY; SPORADIC DISEASE; TEMPORAL CORTEX; CASE CONTROL STUDY; DIFFUSE LEWY BODY DISEASE; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; TEMPORAL LOBE;

ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; DETERGENTS; HSP40 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEWY BODY DISEASE; MOLECULAR CHAPERONES; OCTOXYNOL; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOLUBILITY; TEMPORAL LOBE;

EID: 33644797646     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000190063.90440.69     Document Type: Article

References (68)

1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113-24
2. Gomez-Tortosa E, Ingraham AO, Irizarry MC, et al. Dementia with Lewy bodies. J Am Geriatr Soc 1998;46:1449-58
3. Gomez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-91
4. Gomez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-2009
5. Kruger R, Kuhn W, Leenders KL, et al. Familial parkinsonism with synuclein pathology: Clinical and PET studies of A30P mutation carriers. Neurology 2001;56:1355-62
6. Ma QL, Chan P, Yoshii M, et al. Alpha-synuclein aggregation and neurodegenerative diseases. J Alzheimers Dis 2003;5:139-48
7. Marti MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord 2003;18(suppl 6):S21-27
8. Clayton DF, George JM. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 1998;21:249-54
9. Klucken J, McLean PJ, Gomez-Tortosa E, et al. Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem Res 2003;28:1683-91
10. Ingelsson M, Hyman BT. Disordered proteins in dementia. Ann Med 2002;34:259-71
11. Hyman BT. The neuropathological diagnosis of Alzheimer's disease: Clinical-pathological studies. Neurobiol Aging 1997;18:S27-32
12. Bostantjopoulou S, Katsarou Z, Papadimitriou A, et al. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord 2001;16:1007-13
13. Kalia SK, Lee S, Smith PD, et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron 2004;44:931-45
14. Kitada T, Asakawa S, Matsumine H, et al. Progress in the clinical and molecular genetics of familial parkinsonism. Neurogenetics 2000;2:207-18
15. Klein C, Vieregge P, Hagenah J, et al. Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson's disease from northern Germany. Ann Hum Genet 1999;63:285-91
16. Higuchi S, Arai H, Matsushita S, et al. Mutation in the alpha-synuclein gene and sporadic Parkinson's disease, Alzheimer's disease, and dementia with Lewy bodies. Exp Neurol 1998;153:164-66
17. Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-70
18. Nagar S, Juyal RC, Chaudhary S, et al. Mutations in the alpha-synuclein gene in Parkinson's disease among Indians. Acta Neurol Scand 2001;103:120-22
19. Papadimitriou A, Veletza V, Hadjigeorgiou GM, et al. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: Incomplete penetrance? Neurology 1999;52:651-54
20. Papapetropoulos S, Paschalis C, Athanassiadou A, et al. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:662-65
21. Papapetropoulos S, Ellul J, Paschalis C, et al. Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. Eur J Neurol 2003;10:281-86
22. Polymeropoulos MH. Autosomal dominant Parkinson's disease and alpha-synuclein. Ann Neurol 1998;44:S63-64
23. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-47
24. Bradbury J. Alpha-synuclein gene triplication discovered in Parkinson's disease. Lancet Neurol 2003;2:715
25. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004;364:1167-69
26. Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004;55:174-79
27. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004;364:1169-71
28. Johnson J, Hague SM, Hanson M, et al. SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies. Neurology 2004;63:554-56
29. Singleton A, Gwinn-Hardy K, Sharabi Y, et al. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 2004;127:768-72
30. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841
31. Singleton A, Gwinn-Hardy K. Parkinson's disease and dementia with Lewy bodies: A difference in dose? Lancet 2004;364:1105-7
32. Pals P, Lincoln S, Manning J, et al. Alpha-synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 2004;56:591-95
33. Izumi Y, Morino H, Oda M, et al. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. Neurosci Lett 2001;300:125-27
34. Holzmann C, Kruger R, Saecker AM, et al. Polymorphisms of the alpha-synuclein promoter: Expression analyses and association studies in Parkinson's disease. J Neural Transm 2003;110:67-76
35. Rockenstein E, Hansen LA, Mallory M, et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001;914:48-56
36. Ozawa T, Okuizumi K, Ikeuchi T, et al. Analysis of the expression level of alpha-synuclein mRNA using postmortem brain samples from pathologically confirmed cases of multiple system atrophy. Acta Neuropathol (Berl) 2001;102:188-90
37. Neystat M, Lynch T, Przedborski S, et al. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov Disord 1999;14:417-22
38. Kingsbury AE, Daniel SE, Sangha H, et al. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov Disord 2004;19:162-70
39. Nichols CM, Miller DW, Johnson JM, Young AB. Decreased alpha-synuclein mRNA expression in dementia with Lewy bodies. (Abstract) Soc Neurosci 2001;27:545.5
40. Manning-Bog AB, McCormack AL, Purisai MG, et al. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003;23:3095-99
41. Kobayashi H, Kruger R, Markopoulou K, et al. Haplo insufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease. Brain 2003;126:32-34
42. Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 1998;4:1318-20
43. Weinreb PH, Zhen W, Poon AW, et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 1996;35:13709-15
44. Klucken J, Shin Y, Masliah E, et al. Hsp70 reduces alpha-synuclein aggregation and toxicity. J Biol Chem 2004;279:25497-502
45. Goldberg MS, Lansbury PT Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2000;2:E115-19
46. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: Ubiquitin C-terminal hydrolases. Biochemistry 1998;37:3358-68
47. McLean PJ, Kawamata H, Shariff S, et al. TorsinA and heat shock proteins act as molecular chaperones: Suppression of alpha-synuclein aggregation. J Neurochem 2002;83:846-54
48. McLean PJ, Kawamata H, Hyman BT. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 2001;104:901-12
49. McNaught KS, Belizaire R, Isacson O, et al. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46
50. McNaught KS, Bjorklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002;13:1437-41
51. McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-62
52. Auluck PK, Chan HY, Trojanowski JQ, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002;295:865-68
53. Bonini NM. Chaperoning brain degeneration. Proc Natl Acad Sci U S A 2002; 99(suppl4):16407-11
54. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-2
55. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. J Neuropathol Exp Neurol 1997;56:1095-97
56. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: A commentary. Neurobiol Aging 1997;18:S91-94
57. Newell KL, Hyman BT, Growdon JH, et al. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999;58:1147-55
58. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-59
59. Fink L, Seeger W, Ermert L, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998;4:1329-33
60. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
61. Ardley HC, Scott GB, Rose SA, et al. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J Neurochem 2004;90:379-91
62. Lee HJ, Lee SJ. Characterization of cytoplasmic alpha-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J Biol Chem 2002;277:48976-83
63. Campbell BC, Li QX, Culvenor JG, et al. Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol Dis 2000;7:192-200
64. Sharon R, Bar-Joseph I, Frosch MP, et al. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003;37:583-95
65. Zourlidou A, Payne Smith MD, Latchman DS. HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem 2004;88:1439-48
66. Klucken J, Shin Y, Hyman BT, et al. A single amino acid substitution differentiates Hsp70-dependent effects on alpha-synuclein degradation and toxicity. Biochem Biophys Res Commun 2004;325:367-73
67. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-33
68. Sharma N, Hewett J, Ozelius LJ, et al. A close association of torsinA and alpha-synuclein in Lewy bodies: A fluorescence resonance energy transfer study. Am J Pathol 2001;159:339-44